FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Natera, Inc. Stock AnalysisComprehensive stock analysis for Natera, Inc. (NTRA) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisNTRA
NTRA
Natera, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NTRA
Home🔹Stocks🔹Natera, Inc.

Natera, Inc.

🇺🇸NTRA•NASDAQ

Natera, Inc.

🇺🇸NTRA•NASDAQ
Market cap
$47.11B
Sentiment

Your view on NTRA

Mkt Cap
$47.11B
Sentiment
Your view
NTRA
Natera, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
NTRA
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Natera, Inc.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Steven Leonard Chapman
Headquarters
13011 McCallen Pass Building A, Austin, CA, US
Industry
Medical - Diagnostics & Research
Sector
Healthcare
CEO
Steven Leonard Chapman
Headquarters
13011 McCallen Pass Building A, Austin, CA, US
Description

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.

It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father.

In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection.

The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners.

It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays.

The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Natera, Inc., and the rating behind it. NTRA last traded at $328.93; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Natera, Inc.. Starting points for Natera, Inc.: EPS -$1.34, beta 1.53 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Natera, Inc.. Natera, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Natera, Inc.. Trailing twelve-month EPS for Natera, Inc. stands at -$1.34. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Natera, Inc.. Natera, Inc. has reported as a listed company since 2015. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Natera, Inc. valued side by side against its closest peers. Natera, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Natera, Inc., and how their positions are changing. At a $47.11B market value, institutional positions materially move Natera, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Natera, Inc. executives and directors. Shares of Natera, Inc. have traded between $125.38 and $215.81 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Natera, Inc.. Natera, Inc. is a $47.11B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Natera, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Natera, Inc.. Coverage tracks Natera, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • BNTX — BioNTech SE
  • DGX — Quest Diagnostics Incorporated
  • DXCM — DexCom, Inc.
  • ILMN — Illumina, Inc.
  • IQV — IQVIA Holdings Inc.
  • MTD — Mettler-Toledo International Inc.
  • PHG — Koninklijke Philips N.V.
  • STE — STERIS plc

More Medical - Diagnostics & Research companies

  • ANPCF — Cellbxhealth PLC
  • ARYC — Arrayit Corporation
  • AVCR.V — Avricore Health Inc.
  • AVCRF — Avricore Health Inc.
  • BDSX — Biodesix, Inc.
  • BDX.AX — BCAL Diagnostics Limited
  • BIAF — bioAffinity Technologies, Inc.
  • BIAFW — bioAffinity Technologies, Inc.
  • BIOCQ — Biocept, Inc.
  • BIOQ — Bioqual, Inc.
  • BLLN — BillionToOne, Inc.
  • BMKDF — BioMark Diagnostics Inc.

ETFs holding Natera, Inc.

  • DRKY — VistaShares Target 15 DRUKMacro Distribution ETF (22.67%)
  • HELX — Franklin Genomic Advancements ETF (8.71%)
  • LRNZ — TRUESHARES TECHNOLOGY, AI & DEEP LEARNING ETF (6.60%)
  • BOUT — IBD Breakout Opportunities ETF (6.12%)
  • EKG — First Trust Nasdaq Lux Digital Health Solutions ETF (5.31%)
  • BBH — VanEck Biotech ETF (5.25%)
  • PBE — Invesco Biotechnology & Genome ETF (5.13%)
  • GNOM — Global X - Genomics & Biotechnology ETF (4.86%)

News

Latest Market News